Journal
RENAL FAILURE
Volume 45, Issue 1, Pages -Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/0886022X.2023.2175590
Keywords
Nalfurafine; kappa opioid receptor agonist; hemodialysis; refractory; clinical trial; chronic kidney disease-associated pruritus
Categories
Ask authors/readers for more resources
This study aimed to evaluate the efficacy and safety of nalfurafine in treating refractory CKD-aP in Chinese patients. The results showed that nalfurafine effectively reduced itching and had low incidence of adverse drug reactions.
Background: Chronic kidney disease-associated pruritus (CKD-aP) is very common and sometimes refractory to treatment in hemodialysis patients. In a trial conducted in Japan, nalfurafine, effectively reduced itching of treatment-resistant CKD-aP. Our present bridging study aimed to evaluate the efficacy and safety of nalfurafine in Chinese cohort with refractory CKD-aP. Methods: In this phase III, multicenter bridging study conducted at 22 sites in China, 141 Chinese cases with refractory CKD-aP were randomly (2:2:1) assigned to receive 5 mu g, 2.5 mu g of nalfurafine or a placebo orally for 14 days in a double-blind manner. The primary end point was the mean decrease in the mean visual analogue scale (VAS) from baseline. Results: A total of 141 patients were included. The primary endpoint analysis based on full analysis set (FAS), the difference of mean VAS decrease between 5 mu g nalfurafine and placebo group was 11.37 mm (p = .041); the difference of mean VAS decrease between 2.5 mu g and placebo group was 8.81 mm, but not statistically significantly different. Both differences were greater than 4.13 mm, which met its predefined success criterion of at least 50% efficacy of the key Japanese clinical trial. The per protocol set (PPS) analysis got similar results. The incidence of adverse drug reactions (ADRs) was 49.1% in 5 mu g, 38.6% in 2.5 mu g and 33.3% in placebo group. The most common ADR was insomnia, seen in 21 of the 114 nalfurafine patients. Conclusions: Oral nalfurafine effectively reduced itching with few significant ADRs in Chinese hemodialysis patients with refractory pruritus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available